Cargando…

Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study

Aim: We investigated the safety and efficacy of a long-term combination therapy with fenofibrate and ezetimibe in Japanese patients with combined hyperlipidemia, in comparison with fenofibrate or ezetimibe alone. Methods: The study was a three-arm parallel-group, open-label randomized trial. Eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oikawa, Shinichi, Yamashita, Shizuya, Nakaya, Noriaki, Sasaki, Jun, Kono, Suminori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225135/ https://www.ncbi.nlm.nih.gov/pubmed/27397061 http://dx.doi.org/10.5551/jat.35626

Ejemplares similares

Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs
por: Munro, Matthew J. L., et al.
Publicado: (2021)

A pilot study of the effect of ezetimibe for postprandial hyperlipidemia
por: Xue, E-Zhong, et al.
Publicado: (2018)

Postprandial Hyperlipidemia and Remnant Lipoproteins
por: Masuda, Daisaku, et al.
Publicado: (2017)

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)

A pilot study of the effect of ezetimibe for postprandial hyperlipidemia: Erratum
Publicado: (2018)

Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase
por: van der Veen, Jelske N., et al.
Publicado: (2017)

Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate System and the Physical Stability of Its Amorphous Form
por: Knapik-Kowalczuk, Justyna, et al.
Publicado: (2021)

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
por: Arai, Hidenori, et al.
Publicado: (2018)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Multiparticulate Systems of Ezetimibe Micellar System and Atorvastatin Solid Dispersion Efficacy of Low-Dose Ezetimibe/Atorvastatin on High-Fat Diet-Induced Hyperlipidemia and Hepatic Steatosis in Diabetic Rats
por: Torrado-Salmerón, Carlos, et al.
Publicado: (2021)

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
por: Bao, Wen, et al.
Publicado: (2021)

Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy
por: Grandi, Anna M, et al.
Publicado: (2014)

The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes
por: Shinnakasu, Atsushi, et al.
Publicado: (2017)

The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
por: Wan, Shuling, et al.
Publicado: (2021)

A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia
por: Lella, Meenakshi, et al.
Publicado: (2013)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review
por: Chauhan, Dhruva, et al.
Publicado: (2022)

Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination
por: Wagenhäuser, Isabell, et al.
Publicado: (2023)

Fasting remnant lipoproteins can predict postprandial hyperlipidemia
por: Nagata, Tomoki, et al.
Publicado: (2012)

Safety of routine childhood vaccine coadministration versus separate vaccination
por: Bauwens, Jorgen, et al.
Publicado: (2022)

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
por: Teramoto, Tamio, et al.
Publicado: (2013)

Correction: fasting remnant lipoproteins can predict postprandial hyperlipidemia
por: Nagata, Tomoki, et al.
Publicado: (2014)

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Yamashita, Shizuya, et al.
Publicado: (2022)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017)

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
Publicado: (2005)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
por: Tanaka, Mizue, et al.
Publicado: (2014)

The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
por: Yoon, Hye Eun, et al.
Publicado: (2009)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
por: Ezhov, Marat V., et al.
Publicado: (2023)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Fungal biotransformation of ezetimibe
por: Pervaiz, Irfan, et al.
Publicado: (2014)

BK Viremia Exacerbation With Adalimumab Coadministration
por: Lum, Erik L., et al.
Publicado: (2020)

Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial
por: Shekhar Pandey, A., et al.
Publicado: (2011)

Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2020)

Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis
por: Wang, Chunyang, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
por: Yokote, Koutaro, et al.
Publicado: (2019)

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients
por: Saeedi, Ramesh, et al.
Publicado: (2015)

Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Battaggia, Alessandro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q2aitl37q83c03a93089fbu2q0